reason report
upsid pt
bottom line yesterday market close print strong
beat larg expect believ share could
react posit today meaning guidanc rais
expect midpoint vs beat vs consensu
clariti price limit launch broader
roll-out ada june manag suggest
current assumpt basic flat vs -- per sensor
compar favor mid-to-high teen price declin
believ street potenti even neg price
also impli perhap competit posit
vs mp recently-launch libr -- price
discount -- stronger investor expect
support recent cgm continu glucos monitor
survey link could prompt upward out-year estim revis
street relat specif report strong
quarter sale come y/i ahead
street ahead us out-performance seem
broad-bas intern beat expect
manag cite continu momentum commerci
medicar patient add reflect out-performance continu
momentum throughout year launch manag rais
sale guidanc
reiter op rate pt pt -- previous
-- appli ev/sal now-high estim
share current trade now-high
sale estim premium compar small-cap med-tech
compani nxtm
still reflect notabl contract peak level
believ continu deliv estim upsid also
outlook move higher still lot clariti
new fda reg pipelin product sale estim
move reflect
upsid price instal base growth fda new
cgm classif announc conjunct approv
sever week ago updat know fda
requir secur approv next-gen product notabl type
focus verili fda still threshold new product
meet requir clinic trial major chang
sensor chemistri etc believ new icgm
indic -- integr cgm -- could eas integr insulin
deliveri system pump smart pen enabl featur
thought possibl previous
medic suppli devic
sale
compani inform leerink partner llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate inc share outperform price target longer
term view continu glucos monitor cgm market opportun compel
potenti top estim target larg grow under-tr patient
popul type diabet initi ultim move much-larg type patient
popul seem particularli well-posit within market fda
industri work dilig toward ultim goal develop artifici pancrea -- essenti
cgm-augment insulin pump system automat accur dose patient
new patient adopt momentum -- launch -- like sustain
sale growth near medium term despit competit headwind continu product
evolut includ possibl much less-costli type product conjunct googl
partnership help drive project sale compound-annual-growth-rate period
next month believ share could trade assum
share trade ev/sal estim share current
trade sale estim premium compar small-cap
med-tech compani nxtm still
reflect notabl contract peak level believ continu deliv
estim upsid also drive multipl expans ultim believ
share warrant least modest premium small-cap med-tech stock univers
given massiv highli under-penetrated total address market per
estim consist upsid potenti top-tier growth outlook longer term
risk includ failur success secur fda approv time manner
failur continu evolv sensor technolog includ verili product type patient
toward sensor-integr pump potenti price pressur increas competit
potenti product recal reimburs issu
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except per share data
total good sold
research develop
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
research develop expens
dollar million except per share data
good sold
product good sold
develop good sold
total good sold
incom equiti invest
sg sale
 sale
oper expens sale
compani report leerink partner estim
complet jan earli pre-pivot data mard exce
significantli improv sensor longer
sensor life day vs day current
largest pivot studi ever execut pediatr adult
patient includ one combin studi approxim subject patient
requir spend three in-clin day measur accuraci system similar
studi also work sever artifici pancrea partner
incorpor research clinic studi gather valuabl data
submit commun fda bring first cgm calibr
end
approv calibr approv march
goal introduc
complet trial complet
feb acceler effort verili expect complet
develop
time depend calibr
feb initi feasibl studi complet
publish januari issu journal american medic associ jama
studi show dexcom cgm system user mdi achiev percent averag
reduct week regular use compar baselin
data present ada confer june studi show cgm
user achiev percent averag reduct week regular use
compar percent usual group reli fingerstick blood glucos
partnership verili formerli googl life
scienc develop bandage-lik sensor
togeth data analyt address non-
insulin-us type market sensor
label day
size
phase includ two diabet cohort
random independ
two group group group
phase includ separ independ
random either mdi therapi group
cgm/mdi therapi group
cgm/csii cgm cohort
phase elig phase
phase evalu increment benefit
chang insulin deliveri method
mdi patient alreadi use cgm
multipl daili inject
diabet
spend on-intens program
spend on-intens program
low-end
end
end
end
mid upper mid
rang full year
mid upper mid
rang full year
 remaind
 increas increas
expens strateg initi
expect lower
 increas increas
expens strateg initi
